It is a very important visit because collaboration between the Roswell Park Cancer Institute and the Molecular Immunology Center (CIM) in Cuba is an example of what both countries can advance despite the blockade policy against the Caribbean island, Perdomo said during the meeting.
The government official welcomed the fact that the Office of Foreign Assets Control (OFAC) of the United States Department of Treasury recently extended a license to continue cooperation until 2027.
RPCI President and CEO Candace Johnson stressed that in recent years, a long journey has been covered in this project that has built a relationship of trust between the two institutions.
She added that Cuban scientists are very innovative and develop different approaches to problem solving, so this cooperation can produce many good things for both parties.
Since 2011, the RPCI and the CIM have collaborated in carrying out clinical studies of various products developed by the Cuban institution for the treatment of cancer.
The RPCI was founded in 1898 as the first center of its kind in the United States and today is a leader in cancer research in the world.
The CIM is a closed-cycle biotechnological institution in charge of research, development, production and commercialization of scientific projects, especially for the treatment of cancer and other autoimmune diseases.